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Strengths and limitations of this study
 ► This study assessed the prevalence and factors as-
sociated with fatigue in a general population setting.
 ► A large panel of possible factors associated with fa-
tigue were evaluated.
 ► A list of the most frequent determinants was es-
tablished, facilitating aetiological search in clinical 
practice.
 ► The study was limited to subjects aged 45–86, so 
results do not apply to younger or older groups.
AbStrACt
Objective To assess the prevalence and factors 
associated with fatigue in the general population.
Design Population-based, cross-sectional survey 
performed between May 2014 and April 2017.
Setting General population of the city of Lausanne, 
Switzerland.
Participants 2848 participants (53.2% women, age range 
45–86 years).
Primary outcome measure Prevalence of fatigue the 
previous week, defined as a score of ≥4 using the Fatigue 
Severity Scale.
results The prevalence of fatigue was 21.9% (95% CI 
20.4% to 23.4%) in the total sample. On bivariate analysis, 
participants with fatigue were younger, had a higher body 
mass index, a lower handgrip strength and lower ferritin 
levels. Participants with fatigue were more frequently 
women, had a lower educational level, presented more 
frequently with clinical insomnia, diabetes, anaemia, 
depression and low thyroid stimulating hormone (TSH) 
values, had a higher consumption of antihistamines, 
antidepressants and hypnotics, and rated more frequently 
their health as bad or very bad. Multivariable analysis 
showed that obesity (OR 1.40 (95% CI 1.03 to 1.91)), 
insomnia categories (p value for trend <0.001), depression 
(OR 3.26 (95% CI 2.38 to 4.46)), anaemia (OR 1.70 (95% 
CI 1.00 to 2.89)) and low self-rated health status (p value 
for trend <0.001) were positively associated with fatigue, 
while older age (p value for trend 0.002) was negatively 
associated with fatigue. Conversely, no association was 
found for diabetes, TSH levels, antihistamines or hypnotics.
Conclusion In a population-based sample aged 45–86, 
fatigue was present in one out of five subjects. Regarding 
clinical factors, sleep disturbances such as insomnia 
and sleep apnoea should be assessed first, followed by 
depression. Regarding biological factors, anaemia should 
be ruled out, while screening for hypothyroidism is not 
recommended as a first step. Sleep complaints and fatigue 
in older subjects are not due to ageing and should prompt 
identification of the underlying cause.
IntrODuCtIOn
Fatigue is usually defined as ‘an unpleasant 
physical, cognitive and emotional symptom 
described as a tiredness not relieved by 
common strategies that restore energy’.1 
Fatigue varies in duration and intensity and 
reduces the ability to perform usual daily activ-
ities.1 Indeed, fatigue is a common symptom 
with prevalence rates varying between 4% 
and 45%.2–4 This tenfold range in prevalence 
rates is likely due to the different settings (ie, 
general practice5 or workers6) or the different 
methods used to assess fatigue.7
In healthy subjects, tiredness or sleepi-
ness is a natural occurrence after physical 
or mental efforts and is usually relieved by 
rest,8 9 while fatigue is defined as extreme and 
persistent tiredness, weakness or exhaustion 
of mental and/or physical origin7 that is not 
relieved by rest. Fatigue is defined in dura-
tion as recent (<1 month), prolonged (1–6 
months) and chronic (>6 months).10 When 
unexplained, chronic fatigue can be consid-
ered either as a syndrome (characterised by 
severe, disabling fatigue and other symptoms, 
including musculoskeletal pain, sleep distur-
bance, impaired concentration and head-
aches)11 or as idiopathic (absence of other 
symptoms).
Fatigue is one of the most common 
complaints reported in primary care12 and 
is associated with a decreased quality of life 
and increased morbidity and mortality in 
the general population.13 Fatigue is a multi-
dimensional concept, and several deter-
minants have been proposed. Although a 
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cause (somatic or psychiatric) is identifiable in two thirds 
of fatigue cases, one third of fatigue cases still have no 
specific diagnosis.10 The most frequent diagnoses asso-
ciated with fatigue are viral or upper respiratory tract 
infection, iron deficiency anaemia, adverse effects of 
medication, depression or other mental disorders.14 
Fatigue has also been associated with female sex,8 15 older 
age16 17 and lower socioeconomic status,16 17 although 
the association with the last two determinants were not 
found in some studies.8 18 Importantly, most studies on 
fatigue have been conducted in selected populations, 
such as workers6 or general practice attendees.2 5 18 To our 
knowledge, only two studies have assessed the prevalence 
of fatigue in the general population,8 19 and only a few 
have explored the determinants of fatigue in the general 
population.13 15–17 20 21 Furthermore, most studies focused 
on socioeconomic and disease determinants of fatigue, 
while information regarding the biological determinants 
(ie, anaemia or thyroid pathology)13 or the medications 
associated with fatigue is scarce. Moreover, to date, little 
is known about the prevalence of fatigue and its determi-
nants in Switzerland.
Hence, this study aimed to examine the prevalence and 
the factors associated with fatigue in a population-based 
sample from the city of Lausanne, Switzerland.
POPulAtIOn AnD methODS
Study population
The Cohorte Lausannoise (CoLaus) study is a popu-
lation-based cohort exploring biological, genetic and 
environmental determinants of cardiovascular diseases. 
Detailed descriptions of the study design have been 
reported elsewhere.22 Briefly, a non-stratified random 
representative sample of the population of Lausanne was 
recruited between 2003 and 2006 using the following 
inclusion criteria: (1) aged between 35 and 75 years and 
(2) willingness to participate. The first follow-up was 
performed between April 2009 and September 2012, and 
the second follow-up between May 2014 and April 2017, 
10.9 years on average after the baseline study. At both 
baseline and subsequent follow-ups, participants were 
invited to attend a clinical examination at the Lausanne 
University Hospital. Participants received a paper ques-
tionnaire at home, which they filled in prior to the clinical 
examination. During the clinical examination, a second 
questionnaire regarding personal and family history of 
cardiovascular disease and cardiovascular risk factors was 
applied. For more details, please consult https://www. 
colaus- psycolaus. ch/.
As fatigue was only assessed in the second follow-up, 
data from the second follow-up, which included 4881 of 
the initial 6773 participants recruited at baseline, were 
used. At the second follow-up, participants were aged 
45–86 years.
Fatigue scale
Fatigue severity during the previous week was assessed by 
the nine-item Fatigue Severity Scale (FSS).9 The FSS is 
one of the most commonly used fatigue questionnaires. 
It has been validated in a healthy population setting in 
German-speaking Switzerland,23 Portugal24 and Norway.19 
It is a simple, time-saving, self-administrated question-
naire allowing its use in large epidemiological studies 
and has a high test–retest reliability.7 The questionnaire 
is composed of nine questions; responses are graded 
using a Likert scale from 1 to 7, where 1 indicates strong 
disagreement and 7 strong agreement. The final score 
is the mean value of the nine responses, and a score of 
≥4 is considered as having severe fatigue. This cut-off was 
initially proposed because <5% of healthy controls rate 
their fatigue at that level, whereas 60%–90% of patients 
with medical disorders experience fatigue at or above 
this level.9 An example of the questionnaire in French 
is provided in online supplementary annex 1 and in 
English in online supplementary annex 2. To our knowl-
edge, the French version of the FSS has not yet been vali-
dated in Switzerland. Still, the Cronbach’s alpha for the 
questionnaire was 0.918, suggesting an excellent internal 
consistency.
Covariates
Socioeconomic and lifestyle variables were collected 
using a self-administered questionnaire. Smoking status 
was categorised into never, former and current smoker. 
Educational level was collected at baseline and catego-
rised as obligatory school, apprenticeship, high school/
college or university.
Insomnia was assessed using the Insomnia Severity 
Index (ISI).25 The questionnaire has 16 items evaluating 
the nature, severity and impact of insomnia over the last 
month, namely difficulties falling asleep, sleep mainte-
nance problems, and early morning awakening, sleep 
dissatisfaction, interference of sleep disturbances with 
daytime functioning, noticeability of sleep problems 
by others and distress caused by the sleep difficulties. 
Responses range from 0 ‘Not at all’ to 4 ‘Extremely’. Items 
were scaled 0–4 and then summed to obtain the global 
ISI score (range: 0–28). The questionnaire is provided in 
online supplementary annex 3 in French and in online 
supplementary annex 4 in English. Clinically significant 
insomnia was defined as an ISI score ≥15 (moderate to 
severe intensity).25
Depression was assessed with the Center for Epidemi-
ologic Studies-Depression,26 a 20-item self-report instru-
ment developed for research in the general population 
and is used to assess the severity of depressive symptoms 
over the past week on a 4-point scale. It was translated 
into French by Fuhrer and Rouillon.27 It has been used 
in other recent epidemiological studies assessing the link 
between depression and cardiovascular risk factors.28 The 
questionnaire is composed of 20 questions; responses 
are graded from 0 to 3, where 0 indicates rarely or never 
(less than 1 day), and 4 most or all of the time (5–7 days 
per week). The final score is the sum of the 20 responses 
(possible range is 0–60), and a score of ≥16 is considered 
a risk for depression.
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Self-rated health was assessed by a single question where 
participants had to rate their current health status from 
five categories ranging from ‘very bad’ to ‘very good’. As 
the number of participants rating their health as ‘very 
bad’ was very small, they were grouped with the partici-
pants who rated their health as ‘bad’.
Body weight and height were measured with partici-
pants standing without shoes in light indoor clothing. 
Weight was measured in kilograms to the nearest 0.1 kg 
using a seca scale (seca, Hamburg, Germany). Height 
was measured to the nearest 5 mm using a seca height 
gauge (seca). Body mass index (BMI) was defined as 
weight/height2 and categorised as underweight (BMI 
<18.5 kg/m2), normal (18.5≤BMI<25 kg/m2), overweight 
(25≤BMI<30 kg/m2) and obese (BMI ≥30 kg/m2).
Grip strength was assessed using the Baseline Hydraulic 
Hand Dynamometer (Fabrication Enterprises, Elms-
ford, New York, USA) with the subject seated, shoulders 
adducted and neutrally rotated, elbow flexed at 90°, 
forearm in neutral position, and wrist between 0° and 30° 
of dorsiflexion. Three measurements were performed 
consecutively with the right hand, and the highest value 
(expressed in kilograms) was included in the analyses.
Caffeinated drink consumption was assessed by the 
question ‘How many cups or cans of drinks containing 
caffeine (coffee, tea, coke or similar) do you drink per 
day?’ with possible answers ‘None’, ‘1–3’, ‘4–6’ and ‘7 or 
more’.
Participants were asked to report all medications 
(prescribed or bought over the counter) they took during 
the last 6 months. Medications were coded using the 
WHO’s Anatomical Therapeutic Chemical (ATC) classifi-
cation ( www. whocc. no/ atc_ ddd_ index/). Antihistamines 
were defined as any ATC code beginning with ‘R06’; anti-
depressants were defined as an ATC code beginning with 
‘N05BD’ or ‘N06AA’ or ‘N06AB’ or ‘N06AF’ or ‘N06AG’ 
or ‘N06AX’ or ‘N06CA’; and hypnotics were defined as 
any ATC code beginning with ‘N05C’. Antihypertensive 
drugs were defined by asking the participants if they were 
taking drugs for hypertension.
Diabetes was defined by a fasting plasma glucose 
≥7 mmol/L and/or the presence of an antidiabetic drug 
treatment (oral or insulin). Personal history of cardiovas-
cular disease was assessed by asking the participant if he/
she had sustained a coronary event (myocardial infarc-
tion or angina pectoris) or a stroke.
Biological assays were performed by the Centre Hospi-
talier Universitaire Vaudois (CHUV) Clinical Laboratory 
on fresh blood samples within 2 hours of blood collec-
tion, and additional aliquots were stored at –80°C. All 
measurements were conducted in a Modular P appa-
ratus (Roche Diagnostics, Switzerland). The following 
analytical procedures (with maximum interbatch and 
intrabatch coefficients of variation (CVs)) were used: 
high sensitive C-reactive protein (hs-CRP) by immuno-
assay and latex high sensitive (4.6%–1.3%); transferrin 
by immunoassay (1.8%–1.0%); and glucose by glucose 
dehydrogenase (2.1%–1.0%). Ferritin was assessed by 
immunoturbidimetric method (Tina-quant 4th Genera-
tion, Roche Diagnostics, Switzerland) with a maximum 
intra-assay CV of 7.2% and a maximum interassay CV of 
9.9%. Thyroid stimulating hormone (TSH) and free T4 
were assessed by chemiluminescence on a Cobas e602 
device (Roche Diagnostics, Mannheim, Germany) with 
intrabatch CVs ranging between 1.1% and 3.0% for TSH 
and between 2.7% and 5% for free T4.
exclusion criteria
Participants were excluded if they lacked (1) any answer 
to the fatigue questionnaire; (2) clinical data such as age, 
BMI, smoking, depression, insomnia or medications; 
(3) biological measures such as haemoglobin or thyroid 
hormones; and (4) socioeconomic data such as educa-
tional level.
Patient and public involvement
No patients or public were involved in this study design, 
conduct or analysis.
Statistical analysis
Statistical analysis was performed using Stata V.15.1 for 
Windows. Prevalence rates for fatigue were expressed 
as percentage and 95% CI. Descriptive results were 
expressed as number of participants (percentage) for 
categorical variables or as average ±SD for continuous 
variables. Bivariate analyses were performed using χ2 or 
Fisher’s exact test for categorical variables and Student’s 
t-test or Kruskal-Wallis test for continuous variables. All 
categorical variables significantly (p<0.05) associated 
with fatigue in the bivariate analysis were included in 
the multivariable analysis. Multivariable analysis was 
performed using analysis of variance or logistic regression 
with fatigue (dichotomised into yes/no) as dependent 
variable; results were expressed as multivariable-adjusted 
mean±SE for continuous variables or as OR and 95% CI 
for categorical variables.
Sensitivity analyses were conducted using an FSS 
threshold of 5. Further, as the number of excluded partic-
ipants was high, other sensitivity analyses were conducted 
by creating a propensity score for being excluded.29 The 
propensity score was computed using logistic regression, 
with exclusion (yes/no) as dependent variable and all vari-
ables significantly associated with exclusion as indepen-
dent variables. A probability of exclusion was computed 
for each participant, and the inverse of the probability 
was used for weighting.
Statistical significance was assessed for a two-sided test 
with p<0.05.
reSultS
Study population
Of the 4881 participants in the second follow-up, 2848 
(58.4%) were retained for analysis. The reasons for exclu-
sion are summarised in online supplementary figure 
1; the most frequent reason was lack of data regarding 
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Table 1 Bivariate and multivariable analyses of the continuous factors associated with fatigue as defined by a Fatigue 
Severity Scale score ≥4 in the Cohorte Lausannoise (CoLaus) study, Lausanne, Switzerland, 2014–2017
Bivariate Multivariable
No fatigue Fatigue P value No fatigue Fatigue P value
n 2225 623
Age (years) 61.9±9.8 60.0±9.8 <0.001 – –
BMI (kg/m2) 26.1±4.4 27.4±5.0 <0.001 – –
Handgrip (kg) 35.0±12.0 33.8±12.0 0.022 35.0±0.2 35.3±0.3 0.430
Ferritin (µg/L) 149 (92–229) 139 (83–214) 0.034* 188±4 185±8 0.732
TSH (mUI/L) 2.1 (1.5–3.0) 2.1 (1.5–2.9) 0.374* 2.5±0.1 2.4±0.1 0.332
Free T4 (pmol/L) 16.2±2.5 16.3±2.6 0.190 16.2±0.1 16.4±0.1 0.221
Results are expressed as average ±SD or as median (IQR) for the bivariate analysis and as multivariable-adjusted average ±SE for the 
multivariable analysis. Bivariate analysis performed using Student’s t-test or Kruskal-Wallis non-parametric test (*).Multivariable analysis 
conducted using analysis of variance adjusting for gender, age group, BMI categories, insomnia categories, educational level, diabetes, 
presence of antihistame, antidepressant or hypnotic drugs, self-rated health, and depression.
BMI, body mass index; TSH, thyroid stimulating hormone.
fatigue. The comparison between included and excluded 
participants is provided in online supplementary table 1, 
and the results of the multivariable analysis are provided 
in online supplementary table 2. Excluded partici-
pants were more frequently women, were older, had a 
lower educational level, were more frequently never or 
current smokers, had more comorbidities (cardiovascular 
diseases, diabetes, anaemia and hypertension) and rated 
their health worse.
Prevalence and factors associated with fatigue
The overall prevalence of fatigue as defined by an FSS 
score ≥4 was 21.9% (95% CI 20.4% to 23.4%) and was 
higher in women at 23.4% (95% CI 21.3% to 25.7%) than 
in men at 20.1% (95% CI 18.0% to 22.3%) (p=0.031). 
The distribution of an FSS score ≥5 (prevalence of fatigue 
10.9%) is provided in online supplementary figure 2; the 
number of participants with fatigue decreased when the 
levels of FSS increased.
The analysis of the factors associated with fatigue as 
defined by an FSS score ≥4 is provided in tables 1 and 2.
On bivariate analysis, participants with fatigue were 
younger, had a higher BMI, a lower handgrip strength 
and lower ferritin levels (table 1). Participants with 
fatigue were more frequently women, had a lower educa-
tional level, and presented more frequently with clinical 
insomnia, diabetes, anaemia, depression and low TSH 
values (table 2). Finally, participants with fatigue had a 
higher consumption of antihistamines, antidepressants 
and hypnotics, and rated more frequently their health as 
bad or very bad (table 2).
Multivariable analysis showed that obesity (OR CI 1.40 
(95% CI 1.03 to 1.91)), insomnia categories (p value 
for trend <0.001), depression (OR 3.26 (95% CI 2.38 to 
4.46)), anaemia (OR 1.70 (95% CI 1.00 to 2.89)) and low 
self-rated health status (p value for trend <0.001) were 
positively associated, while older age (p value for trend 
0.002) was negatively associated with fatigue. Conversely, 
no association was found for diabetes, TSH levels, antihis-
tamines or hypnotics (table 2).
Sensitivity analyses
The overall prevalence of fatigue as defined by an FSS 
score ≥5 was 10.9% (95% CI 9.7% to 12.1%) and was 
higher in women at 12.3% (95% CI 10.7% to 14.0%) 
than in men at 9.3% (95% CI 7.8% to 11.1%) (p=0.011). 
The results of the sensitivity analyses using an FSS 
threshold of ≥5 are provided in online supplementary 
tables 3 and 4. Overall, the results were comparable with 
those using a threshold of ≥4: gender, insomnia catego-
ries (p value for trend <0.001) and low self-rated health 
status (p value for trend <0.001) were positively associ-
ated with fatigue. Conversely, no association was found 
for age, obesity, diabetes, TSH levels, antihistamines, 
antidepressants or hypnotics (online supplementary 
table 4).
Sensitivity analysis using inverse probability weighting 
by the propensity score led to similar findings, except 
that anaemia and antidepressants were no longer associ-
ated with fatigue, while a positive association was found 
between low TSH levels and fatigue (online supplemen-
tary table 5).
DISCuSSIOn
To our knowledge, this is one of the few studies assessing 
the prevalence and the factors associated with fatigue in a 
general population setting, and the first study conducted 
in Switzerland. Using an FSS cut-off of ≥4, our results indi-
cate that one out of five people aged between 45 and 86 
years presents with fatigue, and that obesity, insomnia, 
depression and decreasing self-rated health status were 
positively associated with fatigue, while older age was 
negatively associated with fatigue.
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Table 2 Bivariate and multivariable analyses of the categorical factors associated with fatigue as defined by a Fatigue 
Severity Scale score ≥4 in the Cohorte Lausannoise (CoLaus) study, Lausanne, Switzerland, 2014–2017
Bivariate Multivariable
No fatigue Fatigue P value OR (95% CI) P value
Gender 0.031
  Male 1066 (47.9) 268 (43.0) 1 (ref)
  Female 1159 (52.1) 355 (57.0) 1.25 (0.99 to 1.58) 0.065
Age group <0.001
  45–54 643 (28.9) 236 (37.9) 1 (ref)
  55–64 724 (32.5) 209 (33.6) 0.69 (0.53 to 0.90) 0.006
  64–74 626 (28.1) 113 (18.1) 0.43 (0.31 to 0.59) <0.001
  75+ 232 (10.4) 65 (10.4) 0.60 (0.40 to 0.90) 0.013
Educational level 0.017
  Primary 249 (11.2) 93 (14.9) 1 (ref)
  Apprenticeship 794 (35.7) 221 (35.5) 1.05 (0.73 to 1.51) 0.782
  High school 626 (28.1) 182 (29.2) 1.13 (0.78 to 1.64) 0.520
  University 556 (25.0) 127 (20.4) 0.98 (0.66 to 1.46) 0.937
Smoking categories 0.279
  Never 907 (41.7) 242 (39.7) –
  Former 866 (39.8) 264 (43.4) –
  Current 402 (18.5) 103 (16.9) –
BMI categories <0.001
  Underweight 37 (1.7) 5 (0.8) 0.69 (0.24 to 2.01) 0.495
  Normal 920 (41.4) 219 (35.2) 1 (ref)
  Overweight 914 (41.1) 243 (39.0) 1.01 (0.78 to 1.31) 0.942
  Obese 354 (15.9) 156 (25.0) 1.40 (1.03 to 1.91) 0.032
Insomnia categories <0.001
  No insomnia 1782 (86.2) 335 (62.6) 1 (ref)
  Subthreshold 233 (11.3) 114 (21.3) 1.57 (1.16 to 2.13) 0.003
  Clinical insomnia 53 (2.6) 86 (16.1) 3.76 (2.41 to 5.86) <0.001
Caffeinated drinks 0.147
  None 205 (9.5) 75 (12.3) –
  1–3/day 1418 (65.5) 374 (61.5) –
  4–6/day 471 (21.8) 137 (22.5) –
  7+/day 70 (3.2) 22 (3.6) –
Self-rated health <0.001
  Very good 621 (27.9) 58 (9.3) 1 (ref)
  Good 1323 (59.5) 294 (47.2) 1.94 (1.39 to 2.71) <0.001
  Average 270 (12.1) 232 (37.2) 5.55 (3.78 to 8.14) <0.001
  Bad + very bad 11 (0.5) 39 (6.3) 14.1 (5.95 to 33.4) <0.001
Cardiovascular disease 0.697
  No 2036 (91.5) 567 (91.0) –
  Yes 189 (8.5) 56 (9.0) –
Diabetes <0.001
  No 2069 (93.2) 547 (87.9) 1 (ref)
  Yes 151 (6.8) 75 (12.1) 1.24 (0.82 to 1.87) 0.306
Depression (CES-D) <0.001
  No 2026 (93.8) 404 (67.6) 1 (ref)
Continued
Faculte D
e M
edecine. Protected by copyright.
 o
n
 August 29, 2019 at Bibliotheque Centre De Doc De La
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-027070 on 24 August 2019. Downloaded from 
6 Galland-Decker C, et al. BMJ Open 2019;9:e027070. doi:10.1136/bmjopen-2018-027070
Open access 
Bivariate Multivariable
No fatigue Fatigue P value OR (95% CI) P value
  Yes 135 (6.3) 194 (32.4) 3.26 (2.38 to 4.46) <0.001
Anaemia 0.008
  No 2151 (96.7) 588 (94.4) 1 (ref)
  Yes 74 (3.3) 35 (5.6) 1.70 (1.00 to 2.89) 0.049
Ferritin categories 0.436
  >50 2016 (90.6) 558 (89.6) –
  Normal + low 209 (9.4) 65 (10.4) –
TSH categories 0.017
  High (>4.22) 197 (8.9) 56 (9.0) 1.13 (0.77 to 1.66) 0.533
  Normal (0.27–4.22) 2015 (90.6) 556 (89.3) 1 (ref)
  Low (<0.27) 13 (0.6) 11 (1.8) 2.50 (0.91 to 6.85) 0.075
Free T4 categories 0.651
  High (>22) 47 (2.1) 17 (2.7) –
  Normal (12–22) 2122 (95.4) 591 (94.9) –
  Low (<12) 56 (2.5) 15 (2.4) –
Antihypertensives 0.108
  No 1550 (69.7) 413 (66.3) –
  Yes 675 (30.3) 210 (33.7) –
Antihistamines 0.007
  No 2181 (98) 599 (96.2) 1 (ref)
  Yes 44 (2.0) 24 (3.9) 1.30 (0.69 to 2.46) 0.417
Antidepressants <0.001
  No 2062 (92.7) 508 (81.5) 1 (ref)
  Yes 163 (7.3) 115 (18.5) 1.44 (1.02 to 2.04) 0.040
Hypnotics <0.001
  No 2146 (96.5) 580 (93.1) 1 (ref)
  Yes 79 (3.6) 43 (6.9) 0.57 (0.32 to 1.03) 0.062
Results are expressed as the number of participants (row percentage) for the bivariate analysis and as multivariable-adjusted OR (95% 
CI) for the multivariable analysis. Bivariate analysis performed using χ2; multivariable analysis performed using logistic regression. Only 
variables with p<0.05 in the bivariate analysis were retained for the multivariable analysis.
–, not retained; BMI, body mass index; CES-D, Center for Epidemiologic Studies-Depression; TSH, thyroid stimulating hormone; ref, 
reference.
Table 2 Continued
Prevalence of fatigue
Using the cut-off of ≥4, fatigue was present in one out 
of five participants (22.1%), a finding in agreement with 
the study by Loge et al,8 which reported a prevalence of 
22% among 2323 participants using the Chalder Fatigue 
Scale. Conversely, the cross-sectional study by Lerdal et 
al,19 which used the FSS in a sample of 1893 participants, 
reported a prevalence of fatigue of 46.7% and 23.1% 
using a cut-off of ≥4 and ≥5, respectively, in comparison 
with 22.1% and 10.9% in our study. The investigated 
population was aged 19–81 years and included younger 
participants (women of childbearing age with menstrua-
tion and young parents), compared with our study which 
included participants aged between 45 and 86 years, 
which could explain this difference in the prevalence of 
fatigue. A study conducted in general practice reported 
a prevalence of fatigue of 38% using the Chalder Fatigue 
Scale,2 whereas a study conducted in the Dutch working 
population reported a prevalence of fatigue of 22% using 
other fatigue measures.6 Comparison between studies 
is hampered by the small number of studies assessing 
the prevalence of fatigue in non-selected samples, the 
different fatigue scales used and the somewhat different 
settings (ie, general population vs general practice). Still, 
they provide a first basis for comparison, and it would 
be important that future studies use similar assessment 
methods to facilitate comparisons. Overall, our results 
suggest that the prevalence of fatigue in the Laus-
anne population is comparable or lower than reported 
previously.
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Clinical and societal factors associated with fatigue
Women tended to report fatigue more frequently than 
men, but this association was no longer significant after 
multivariable adjustment. Higher prevalence of fatigue 
in women has been found in some studies8 15 but not in 
others.18 In a Swedish study conducted in 2014, Engberg 
et al16 considered that this difference could be due to 
factors related to gender inequalities regarding house-
hold responsibilities and child raising, as the gender gap 
in general fatigue was largest among those aged <55 years.
Younger people reported fatigue more frequently than 
the elderly, a finding in agreement with a Swedish study 
conducted in 2014.16 Similarly, a previous study found 
that older subjects complain less of sleepiness.30 Still, this 
association was no longer statistically significant when the 
cut-off of ≥5 was applied to define fatigue, suggesting that 
young subjects tend to present with borderline fatigue 
as suggested previously.19 Conversely, earlier studies 
(1990–2000) found a positive association between age 
and fatigue.8 17 21 A possible explanation for this differ-
ence is that older people might have a better quality of 
life nowadays and are less depressed. Although there 
is little information regarding trends in quality of life 
among Swiss elderly, the "Vivre/Leben/Vivere" study31 
concluded that the quality of life among Swiss elderly 
increased in the last 30 years.32 Indeed, in our study, the 
lowest prevalence of fatigue was reported by participants 
aged 64–74 years, which are the ‘young’ retired with few 
comorbidities. Similarly, the prevalence of depression 
was lower in elderly than in younger participants (8.1% 
and 10.2% in the 65–74 and the 75+ years, respectively, vs 
15.1% and 12.5% in the 45–54 and 55–64 years, respec-
tively; p<0.001).
Obese subjects had a higher prevalence of fatigue 
defined by an FSS score ≥4. This finding is in agreement 
with studies conducted in the USA33 and in the UK.13 Still, 
this association was no longer statistically significant when 
the cut-off of ≥5 was applied to define fatigue, suggesting 
that obese subjects tend to present with borderline fatigue 
as suggested previously.19 Obesity is a risk factor for sleep 
apnoea, which leads to increased daytime sleepiness. Still, 
the association persisted after adjusting for insomnia, a 
finding in agreement with a previous study that showed 
that obese subjects have excessive fatigue independently 
of sleep-disordered breathing.34 Because it excluded too 
many subjects, we did not correlate obesity and sleep-dis-
ordered breathing in our study. A possible explanation 
could be the increase in proinflammatory cytokines in 
obese subjects,35 which would lead to higher fatigue,36 but 
other factors such as decreased physical fitness should be 
further explored.
A positive association was found between self-reported 
clinical insomnia and fatigue, and this association was 
independent of obesity, depression and antidepressant 
medication. Fatigue is a core symptom of insomnia,34 
and a Norwegian study conducted in 2014 showed that 
reducing insomnia severity led to a concomitant reduc-
tion in fatigue.37 Interestingly, many subjects with sleep 
complaints do not consult for this issue,38 which might 
lead to an underestimation of its prevalence. Overall, our 
results suggest that insomnia is an important and under-
estimated factor of fatigue.
Both depression and antidepressant medication were 
independently and positively associated with fatigue. The 
association between depression and fatigue has been 
repeatedly reported,13 39–41 and the same applies for anti-
depressant medication.3 Our results confirm the known 
association between depression and fatigue, and suggest 
that antidepressant treatment might not systematically 
relieve fatigue among subjects with depression. Further-
more, fatigue is a common side effect of antidepressant 
therapy and a symptom of depression, making the identi-
fication of the cause of fatigue difficult with a possibility 
of reverse causality (fatigue leading to depression and 
vice versa). We used a one-dimensional tool to evaluate 
fatigue (FSS); hence, we cannot distinguish between phys-
ical and mental fatigue. There is considerable overlap in 
the phenomenology of fatigue and depression or anxiety, 
but there are some important differences. People with 
fatigue without psychiatric symptoms tend to attribute 
their symptoms to external causes, while most depressed 
people experience self-blame or lowered self-esteem.42 
Further, fatigue and depression commonly appear 
together. A study conducted in 2009 by Harvey et al43 
showed that 7% of fatigued persons have no psychiatric 
symptoms, but remain at increased risk of later psychi-
atric disorder independently of the severity of fatigue.
A strong association was found between poor self-rated 
health and fatigue, a finding also reported elsewhere.6 16 
Low self-rated health has been associated with increased 
levels of inflammatory markers such as interleukin 6 and 
CRP,44 which in turn could trigger fatigue. Conversely, 
increased fatigue might lead to a lower rating of health 
status.
biological factors associated with fatigue
Participants with anaemia had a higher likelihood of 
reporting fatigue. This finding is in agreement with the 
literature,45 46 although no association between fatigue 
and low haemoglobin levels was found in a UK study.13 
A possible explanation is that in the UK study, anaemia 
was defined as a haemoglobin <110 g/L, which is lower 
than the thresholds used in our study (<133 g/L for men 
and <117 g/L for women). This led to a small sample size 
(356 participants, corresponding to 1.9% of the overall 
sample) and thus a low statistical power.
Hypothyroidism is often cited during the investigation 
of fatigue.10 In this study, participants with low TSH levels 
reported fatigue more frequently, but this association was 
significant only after multivariable analysis with inverse 
probability weighting. Furthermore, the prevalence of 
low TSH levels was <1% in the overall sample. The asso-
ciations between hypothyroidism and fatigue have been 
controversial for a long time.10 Basu et al13 found no associ-
ation between TSH categories and fatigue, and Canaris et 
al47 reported that the association between hypothyroidism 
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and fatigue was weak. Overall, our results suggest that, in 
the presence of fatigue, hypothyroidism is an unlikely 
cause and should not be systematically assessed.
Implications of the study
Based on our study findings, we propose to focus on 
specific clinical and biological factors amenable to treat-
ment at an individual level. Regarding clinical factors, 
sleep disturbances such as insomnia and sleep apnoea 
(namely in the presence of a patient with obesity) and 
the presence of depression should be assessed. Lifestyle 
measures to improve sleep quality and quantity should 
be preferred to medication.22 In the case of depression, 
it will be important to warn patients that antidepressant 
medication might not necessarily lead into rapid relief 
of fatigue. Regarding biological factors, anaemia should 
be ruled out, while screening for hypothyroidism is not 
recommended as a first step.
At the population level, preventive measures such as 
stress management and health promotion like relaxation, 
time management and cognitive reframing (eg, within the 
work environment) could improve sleep quality, increase 
self-rated health48 and consequently reduce fatigue.
Strengths and limitations
This study has several strengths. First, it is one of the few 
studies assessing the prevalence and the factors associ-
ated with fatigue in a population-based sample, which is 
of interest for public health. Second, it explored a large 
panel of possible factors associated with fatigue, thus 
allowing the identification of factors significantly and 
independently associated with fatigue.
This study has also several limitations. First, its cross-sec-
tional setting precludes the identification of the causes of 
fatigue, as reverse causality is possible (ie, fatigue leading to 
depression and vice versa).3 All participants of the CoLaus 
study are currently being recontacted and re-examined, 
so a prospective analysis of the causes of fatigue will be 
feasible within 2 years. Second, there is no gold standard 
for the evaluation of fatigue and no official definition of 
fatigue. Hence, results might vary according to the scale 
applied or how participants interpret the term ‘fatigue’. 
In this study, we chose to use a scale that was previously 
applied by other authors to facilitate comparisons. Third, 
only the German version of the FSS has been validated 
in Switzerland; the French version used in this study has 
not yet been validated. Hence, it is possible that the true 
prevalence levels of fatigue might be underestimated or 
overestimated, or that some items of the questionnaire 
might not be informative. Still, the Cronbach’s alpha 
for the questionnaire was 0.918, suggesting an excellent 
internal consistency. Furthermore, our results provide a 
first estimation of the prevalence of fatigue in the Swiss 
French-speaking general population, which could serve as 
a reference for further studies. Fourth, a sizeable fraction 
of the sample was excluded, both between the baseline 
and the second follow-up, and within the current study, 
which might limit the generalisability of the findings. For 
instance, excluded participants were more frequently 
women; as women reported more frequently fatigue, this 
might lead to an underestimation of prevalence rates or a 
decrease in the strength of the associations. Still, an anal-
ysis using a propensity score weighting for the probability 
of being excluded led to similar findings. Conversely, it 
was not possible to assess the reasons why participants 
did not complete the questionnaire. Fifth, no informa-
tion was available regarding shift work or the presence of 
very young children. Still, as a sizeable fraction (almost 
70%) of the sample was aged over 55 and over 36% of 
the sample was aged over 64, it is likely that the number 
of participants either on shift work or with very young 
children would be small. Sixth, the FSS explored fatigue 
during the previous week, while the ISI score explored 
sleep during the previous month. Hence, it is possible 
that the time association between the two variables might 
not be optimal. Still, as the FSS lies within the period 
encompassed by the ISI, we believe that the associations 
obtained are clinically relevant. Seventh, the study is 
limited to the population of aged 45–86, and its general-
isability remains to be assessed. For instance, no informa-
tion was collected regarding other confounders among 
younger subjects, where prevalence of fatigue might be 
higher due to parental and professional duties.49 Finally, 
possible biases related to the self-reporting of fatigue 
could not be avoided, such as overestimation or under-
estimation of symptoms or misunderstanding of what the 
term ‘fatigue’ meant; still, this dilution bias would lead to 
a decrease in the strength of the associations, and it would 
be too restrictive in our opinion to provide a definition of 
the term ‘fatigue’ to the participants, as different inter-
pretations of the definition itself could also occur.
recommendations for future studies
Future studies on the prevalence of fatigue in the general 
population should focus on the following topics: (1) vali-
date the questionnaires in the population of interest; and 
(2) whenever possible, use a standardised questionnaire 
to allow comparison between studies.
While some factors such as obesity,13 33 depression13 39–41 
and antidepressant medications3 were consistently asso-
ciated with fatigue in our study and in the literature, 
controversial findings such as the association between 
fatigue and gender, age groups and anaemia should be 
further explored.
COnCluSIOn
In a population-based sample aged 45–86, fatigue was 
present in one out of five subjects. Regarding clinical 
factors, sleep disturbances such as insomnia and sleep 
apnoea should be assessed first, followed by depression. 
Regarding biological factors, anaemia should be ruled 
out, while screening for hypothyroidism is not recom-
mended as a first step. Sleep complaints and fatigue in 
older subjects are not due to ageing and should prompt 
the identification of the underlying cause.
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